Adynovate

 (rurioctocog alfa pegol) Takeda

Composition:

Adynovate 250 and 500 International Units (IU).

Adynovate [rurioctocog alfa pegol, Recombinant Coagulation Factor VIII (rch), PEGylated] is supplied in single-use vials containing nominal potencies of 250 and 500IU per vial with a diluent vial containing sterile water for injections for reconstitution to 2 mL.

The 2 mL diluent of water for injections is available for Adynovate 250 and 500 IU.

The amounts of the inactive ingredients are constant in all strengths.

Indications:

Adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia A (congenital factor VIII deficiency) patients for:

-   Control and prevention of bleeding episodes

-   Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

-   Perioperative management (surgical prophylaxis)

Adynovate is not indicated for the treatment of von Willebrand disease.